References

• Bousman, C. A., Oomen, A., Jessel, C. D., Tampi, R. R., Forester, B. P., Eyre, H. A., Lavretsky, H., & Müller, D. J. (2022). Perspectives on the Clinical Use of Pharmacogenetic Testing in Late-Life Mental Healthcare: A Survey of the American Association of Geriatric Psychiatry Membership. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 30(5), 560–571. https://doi-org.ezproxy.lib.ucalgary.ca/10.1016/j.jagp.2021.09.013
• Bousman, C. A., Maruf, A. A., Marques, D. F., Brown, L. C., & Müller, D. J. (2023). The emergence, implementation, and future growth of pharmacogenomics in psychiatry: a narrative review. Psychological medicine, 53(16), 7983–7993. https://doi-org.ezproxy.lib.ucalgary.ca/10.1017/S0033291723002817
• Bousman, C. A., Stevenson, J. M., Ramsey, L. B., Sangkuhl, K., Hicks, J. K., Strawn, J. R., Singh, A. B., Ruaño, G., Mueller, D. J., Tsermpini, E. E., Brown, J. T., Bell, G. C., Leeder, J. S., Gaedigk, A., Scott, S. A., Klein, T. E., Caudle, K. E., & Bishop, J. R. (2023). Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clinical pharmacology and therapeutics, 114(1), 51–68. https://doi-org.ezproxy.lib.ucalgary.ca/10.1002/cpt.2903
• Maruf, A. A., & Bousman, C. A. (2022). Approaches and hurdles of implementing pharmacogenetic testing in the psychiatric clinic. PCN reports : psychiatry and clinical neurosciences, 1(2), e26. https://doi-org.ezproxy.lib.ucalgary.ca/10.1002/pcn5.26
• Stingl, J. C., & Viviani, R. (2025). Pharmacogenetic guided drug therapy - how to deal with phenoconversion in polypharmacy. Expert opinion on drug metabolism & toxicology, 21(4), 399–407. https://doi-org.ezproxy.lib.ucalgary.ca/10.1080/17425255.2025.2451440